Sumitomo Pharma America, Inc.

Sumitomo Pharma America, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
1984-01-01
Employees
5K
Market Cap
-
Website
http://www.sunovion.com

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

First Posted Date
2016-04-12
Last Posted Date
2020-03-27
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
132
Registration Number
NCT02734693
Locations
🇺🇸

Avida Inc, Newport Beach, California, United States

🇺🇸

Meridien Research, Bradenton, Florida, United States

🇺🇸

Bayou City Research, Ltd, Houston, Texas, United States

and more 2 locations

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

First Posted Date
2016-04-06
Last Posted Date
2023-11-14
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
177
Registration Number
NCT02729298
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

US Oncology - Texas Oncology - Fort Worth, Fort Worth, Texas, United States

and more 13 locations

Dasotraline Binge Eating Disorder Extension Study

Phase 3
Completed
Conditions
Interventions
First Posted Date
2016-02-17
Last Posted Date
2020-08-12
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
533
Registration Number
NCT02684279
Locations
🇺🇸

Neuotrials Research, Inc., Atlanta, Georgia, United States

🇺🇸

Boston Clinical Trials, Boston, Massachusetts, United States

🇺🇸

Texas Center for Drug Development, Inc., Houston, Texas, United States

and more 49 locations

Dasotraline Binge Eating Disorder Study

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-09-30
Last Posted Date
2017-09-28
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
319
Registration Number
NCT02564588
Locations
🇺🇸

PCSD- Feighner Research, San Diego, California, United States

🇺🇸

Capstone Clinical Research, Libertyville, Illinois, United States

🇺🇸

Sunstone Medical Research, LLC, Medford, Oregon, United States

and more 34 locations

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-09-07
Last Posted Date
2023-11-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
496
Registration Number
NCT02542696
Locations
🇺🇸

Keck Medical Center at USC, Los Angeles, California, United States

🇺🇸

Clinical Trials, Inc., Little Rock, Arkansas, United States

🇺🇸

UC Irvine Health Gottschalk Medical Plaza, Irvine, California, United States

and more 67 locations

An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate

Terminated
Conditions
Interventions
First Posted Date
2015-08-13
Last Posted Date
2021-01-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
121
Registration Number
NCT02520557
Locations
🇺🇸

University of Pennsylvania Perlman School of Medicine, Philadelphia, Pennsylvania, United States

Alvocidib Biomarker-driven Phase 2 AML Study

First Posted Date
2015-08-11
Last Posted Date
2023-11-15
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
104
Registration Number
NCT02520011
Locations
🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

Morristown Cancer Center, Morristown, New Jersey, United States

and more 35 locations

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

First Posted Date
2015-07-15
Last Posted Date
2023-11-14
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
24
Registration Number
NCT02498665
Locations
🇺🇸

Horizon Oncology Research, Lafayette, Indiana, United States

🇺🇸

USOR - TX Oncology Austin, Austin, Texas, United States

🇺🇸

USOR - TX Oncology Tyler, Tyler, Texas, United States

and more 5 locations

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

Completed
Conditions
Interventions
First Posted Date
2015-07-07
Last Posted Date
2018-02-07
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
71
Registration Number
NCT02491073
Locations
🇺🇸

Mid-Atlantic Epilepsy Center, Bethesda, Maryland, United States

🇺🇸

Consultans in Epilepsy & Neurology, PLLC, Boise, Idaho, United States

🇺🇸

Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States

and more 4 locations

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

First Posted Date
2015-06-26
Last Posted Date
2023-11-14
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
165
Registration Number
NCT02483247
Locations
🇺🇸

Indiana University Health Goshen, Goshen, Indiana, United States

🇺🇸

Louisiana State Univesity, New Orleans, Louisiana, United States

🇨🇦

Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath